MX2011004219A - Vacuna contra el virus de la peste equina africana. - Google Patents

Vacuna contra el virus de la peste equina africana.

Info

Publication number
MX2011004219A
MX2011004219A MX2011004219A MX2011004219A MX2011004219A MX 2011004219 A MX2011004219 A MX 2011004219A MX 2011004219 A MX2011004219 A MX 2011004219A MX 2011004219 A MX2011004219 A MX 2011004219A MX 2011004219 A MX2011004219 A MX 2011004219A
Authority
MX
Mexico
Prior art keywords
sickness virus
african horse
horse sickness
vaccine against
against african
Prior art date
Application number
MX2011004219A
Other languages
English (en)
Inventor
Jiansheng Yao
Jules Maarten Minke
Jean-Christophe Audonnet
Alan John Guthrie
Nigel James Maclachlan
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011004219(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of MX2011004219A publication Critical patent/MX2011004219A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona vectores que contienen y expresan in vivo los genes que codifican VP2 y VP5 del Virus de Enfermedad de Caballo Africano o un epítope del mismo que induce una respuesta inmune en un caballo contra el virus de enfermedad de caballo Africano, composiciones que comprenden los vectores, métodos de vacunación contra el virus de enfermedad de caballo Africano y equipos para el uso con tales métodos y composiciones.
MX2011004219A 2008-10-24 2009-10-22 Vacuna contra el virus de la peste equina africana. MX2011004219A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10807508P 2008-10-24 2008-10-24
US16351709P 2009-03-26 2009-03-26
PCT/US2009/061669 WO2010048394A2 (en) 2008-10-24 2009-10-22 Vaccine against african horse sickness virus

Publications (1)

Publication Number Publication Date
MX2011004219A true MX2011004219A (es) 2011-09-22

Family

ID=41818403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011004219A MX2011004219A (es) 2008-10-24 2009-10-22 Vacuna contra el virus de la peste equina africana.

Country Status (19)

Country Link
US (3) US8168200B2 (es)
EP (1) EP2358742B1 (es)
JP (1) JP2012506699A (es)
KR (1) KR101719005B1 (es)
CN (1) CN102245627A (es)
AP (1) AP3334A (es)
AR (1) AR074055A1 (es)
AU (1) AU2009308331C1 (es)
BR (2) BR122019001455B1 (es)
CA (1) CA2741333C (es)
CL (1) CL2011000922A1 (es)
EA (1) EA024111B1 (es)
ES (1) ES2681693T3 (es)
MX (1) MX2011004219A (es)
NZ (2) NZ592388A (es)
PL (1) PL2358742T3 (es)
PT (1) PT2358742T (es)
WO (1) WO2010048394A2 (es)
ZA (1) ZA201103031B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2358742T3 (pl) * 2008-10-24 2018-08-31 Merial, Inc. Szczepionka przeciwko wirusowi afrykańskiego pomoru koni
JP6260972B2 (ja) 2012-02-14 2018-01-17 メリアル インコーポレイテッド 狂犬病タンパク質及びｏｘ４０タンパク質の両方を発現する組換えポックスウイルスベクター並びに前記ベクターから製造されるワクチン
WO2016071850A1 (en) * 2014-11-04 2016-05-12 Deltamune (Pty) Limited Live attenuated african horsesickness virus
US10574993B2 (en) 2015-05-29 2020-02-25 Qualcomm Incorporated Coding data using an enhanced context-adaptive binary arithmetic coding (CABAC) design
EP3768326A1 (en) * 2018-03-19 2021-01-27 Boehringer Ingelheim Vetmedica GmbH Ehv insertion site ul43
CN116041447A (zh) * 2022-12-29 2023-05-02 北京亿森宝生物科技有限公司 一种检测非洲马瘟病毒的试剂盒及其应用
CN116656731B (zh) * 2023-05-25 2024-04-12 军事科学院军事医学研究院军事兽医研究所 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
ZA976424B (en) 1996-07-05 1999-01-22 Agricultural Research Council Nucleic acid sequences coding for african horsesickness virus outer capsid components
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US7862821B2 (en) * 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
PL2358742T3 (pl) * 2008-10-24 2018-08-31 Merial, Inc. Szczepionka przeciwko wirusowi afrykańskiego pomoru koni

Also Published As

Publication number Publication date
CA2741333A1 (en) 2010-04-29
PL2358742T3 (pl) 2018-08-31
ES2681693T3 (es) 2018-09-14
EA024111B1 (ru) 2016-08-31
CL2011000922A1 (es) 2011-09-16
AR074055A1 (es) 2010-12-22
AU2009308331B2 (en) 2014-08-21
EA201100674A1 (ru) 2011-12-30
CA2741333C (en) 2018-02-13
US8168200B2 (en) 2012-05-01
JP2012506699A (ja) 2012-03-22
NZ592388A (en) 2012-03-30
AP2011005954A0 (en) 2011-10-31
BRPI0920622A8 (pt) 2019-02-05
BRPI0920622A2 (pt) 2016-10-04
US20140120133A1 (en) 2014-05-01
AU2009308331C1 (en) 2015-07-09
WO2010048394A2 (en) 2010-04-29
EP2358742B1 (en) 2018-02-28
PT2358742T (pt) 2018-06-04
US20100119546A1 (en) 2010-05-13
KR101719005B1 (ko) 2017-03-22
EP2358742A2 (en) 2011-08-24
AP3334A (en) 2015-07-31
US20120114691A1 (en) 2012-05-10
BRPI0920622B1 (pt) 2019-11-12
KR20110092281A (ko) 2011-08-17
AU2009308331A1 (en) 2010-04-29
CN102245627A (zh) 2011-11-16
BR122019001455B1 (pt) 2021-01-19
WO2010048394A3 (en) 2010-08-19
NZ598605A (en) 2014-04-30
ZA201103031B (en) 2014-03-26

Similar Documents

Publication Publication Date Title
MX2011004219A (es) Vacuna contra el virus de la peste equina africana.
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX361893B (es) Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos.
MA40151B2 (fr) Vaccins de recombinaison fmdv et leurs utilisations
EP2944322A3 (en) Bluetongue virus recombinant vaccines and uses thereof
MX2008016036A (es) Vacuna viral recombinante.
MY159543A (en) Recombinant avian influenza vaccine and uses thereof
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2011103417A3 (en) Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
EP3156070A3 (en) Newcastle disease virus vectored herpesvirus vaccines
MX351643B (es) Antigeno ndv recombinante y usos del mismo.
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
NZ608143A (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
MX2010010457A (es) Vectores recombinantes de rinovirus.
NZ700470A (en) Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
TN2009000195A1 (en) Prime boost canine leishmania vaccine
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
MX348137B (es) Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
MX2017008087A (es) Virus de la viruela porcina recombinante y vacunas.
MX351642B (es) Vacuna para virus de leucemia felina recombinante que contiene gen de envoltura del virus de leucemia felina optimizado.
MX2010008170A (es) Vacunas para influenza canina.
MX2013013812A (es) Vacunas geneticas contra el virus hendra y el virus nipah.
WO2016077580A3 (en) Compositions and methods for treating melanoma
PH12018500372A1 (en) Fcv recombinant vaccines and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration